These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1539343)

  • 1. Triple drug maintenance therapy in renal transplantation.
    Pallardó LM; Sánchez J; Hernandez M; Górriz JL; Sánchez P; Beneyto I; Rochera A
    Transplant Proc; 1992 Feb; 24(1):58-9. PubMed ID: 1539343
    [No Abstract]   [Full Text] [Related]  

  • 2. Late acute rejection in renal transplant recipients: response to steroid treatment.
    Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
    Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
    [No Abstract]   [Full Text] [Related]  

  • 3. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract]   [Full Text] [Related]  

  • 4. Five-year experience with a triple drug protocol in renal transplantation.
    Pallardó LM; Sánchez J; García J; Puig N; Sánchez P; Górriz JL; Cruz JM
    Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection.
    Gaber LW; Moore LW; Alloway RR; Flax S; Gaber AO
    Transplant Proc; 1995 Feb; 27(1):1019. PubMed ID: 7878784
    [No Abstract]   [Full Text] [Related]  

  • 6. OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation.
    Cantarovich D; Hourmant M; Dantal J; Giral M; Paineau J; Karam G; Soulillou JP
    Transplant Proc; 1994 Apr; 26(2):549. PubMed ID: 8171548
    [No Abstract]   [Full Text] [Related]  

  • 7. Ganciclovir treatment for cytomegalovirus infections in renal transplant recipients.
    Buturović-Ponikvar J; Kandus A; Malovrh M; Ponikvar R; Kveder R
    Transplant Proc; 1992 Oct; 24(5):1921-3. PubMed ID: 1329287
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuncts to triple-drug therapy after cardiac transplantation: a comparison of Nashville rabbit antithymocyte serum to OKT3.
    Aziz S; Kruse AP; Roby PV; Allen MD; Khan K; Fishbein D
    Transplant Proc; 1994 Oct; 26(5):2721-3. PubMed ID: 7940852
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytokine-release syndrome: differences between high and low doses of OKT3.
    Norman DJ; Kimball JA; Barry JM
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequential monitoring of immunoregulatory T cell subsets in renal transplantation.
    Mestre M; González C; Griño JM; Valls A; Bonete J; Mané E; Corominas M; Bas J; Romeu A; Buendia E
    Transplant Proc; 1992 Feb; 24(1):73-5. PubMed ID: 1539351
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical results of quadruple drug immunosuppression in liver transplantation.
    Fabregat J; Fradera R; Jaurrieta E; Figueras J; Rafecas A; Rufi G; Casanovas T; Casais L; Gil Vernet S
    Transplant Proc; 1992 Feb; 24(1):148-9. PubMed ID: 1539217
    [No Abstract]   [Full Text] [Related]  

  • 12. Posttransplant renal allograft dysfunction as a prognostic factor in triple therapy-treated patients.
    Pallardó LM; García J; Sánchez J; Górriz JL; Orero E; Calabuig F
    Transplant Proc; 1992 Feb; 24(1):113-4. PubMed ID: 1539199
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma exchange in highly sensitized patients as induction therapy after renal transplantation.
    Reisaeter AV; Fauchald P; Leivestad T; Holdaas H; Hartmann A; Pfeffer P; Sødal G
    Transplant Proc; 1994 Jun; 26(3):1758. PubMed ID: 8030121
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
    Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
    Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimization of cyclosporine monotherapy--long-term graft function.
    Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
    Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategy for improving retransplantation in the CyA era.
    Dickerman R; Langley J; Brinker K; Trevino G; Melton L; Vergne-Marini P; Wilson PK
    Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292
    [No Abstract]   [Full Text] [Related]  

  • 18. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
    Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
    Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
    Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
    Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of cyclosporine dose on long-term outcome after heart transplantation.
    Valantine H; Hunt S; Gamberg P; Miller J; Luikart H
    Transplant Proc; 1994 Oct; 26(5):2710-2. PubMed ID: 7940848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.